jetcityimage/iStock Editorial via Getty Images
- Eli Lilly (NYSE:LLY) announced Monday that the two highest doses of its weight loss therapy, Zepbound, will be available for sale as single-dose vials on its direct-to-consumer platform, LillyDirect.
- Accordingly, 12.5 mg and 15 mg doses of the injectable, also known as tirzepatide, will be offered through LillyDirect’s Self-Pay Pharmacy Solutions and the Zepbound Self-Pay Journey Program.
- Healthcare providers can prescribe those vials on July 7, and the company will begin shipments in early August, the Indiana-based drugmaker said.
- With this decision, all FDA-approved dose strengths of Zepbound will be available for $499 per month or less for any overweight or obese adult with a weight-related medical condition, regardless of insurance coverage.
- In March, rival Novo Nordisk (NVO) (OTCPK:NONOF) launched its direct-to-consumer (DTC) platform, NovoCare Pharmacy, offering all dose strengths of its weight loss therapy, Wegovy, to eligible patients regardless of their healthcare coverage.
More on Eli Lilly
- Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
- Eli Lilly: If You Don’t Buy On Weight Loss Promise Now, You Probably Never Will
- Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
- Eli Lilly’s early-stage obesity drug causes up to 11% of weight loss in three months
- Short bets on S&P 500 Healthcare sector ease in May; MRNA stays most shorted stock